Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 6, 2010, Pages 506-510

  Fahrtash, Farzan ^a   McCahon, Emma ^a,b   Arbuckle, Susan ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Kaposiform hemangioendothelioma; Tufted angioma; Vincristine

Indexed keywords

VINCRISTINE; ANTINEOPLASTIC AGENT;

ANALGESIA; ANGIOMA; ARTICLE; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMANGIOENDOTHELIOMA; HUMAN; INFANT; KAPOSI SARCOMA; KAPOSIFORM HEMANGIOENDOTHELIOMA; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; TUFTED ANGIOMA; UNSPECIFIED SIDE EFFECT; VASCULAR TUMOR; HEMANGIOMA; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMANGIOENDOTHELIOMA; HEMANGIOMA; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 77955911490     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e001a9     Document Type: Article

References (30)

1. Fernandez Y, Bernabeu-Wittel M, García-Morillo JS. Kaposiform hemangioendothelioma. Eur J Intern Med. 2009;20: 106-113.
2. Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol. 2004;28:559-568.
3. Kasabach H, Merritt K. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child. 1940;59:1063-1070.
4. Brasanac D, Janic D, Boricic I, et al. Retroperitoneal kaposiform hemangioendothelioma with tufted angioma-like features in an infant with Kasabach-Merritt syndrome. Pathol Int. 2003;53:627-631.
5. Beaubien ER, Ball NJ, Storwick GS. Kaposiform heman-gioendothelioma: a locally aggressive vascular tumor. JAm Acad Dermatol. 1998;38(5 Pt 2):799-802.
6. Kim DW, Chung JH, Ahn SH, et al. Laryngeal kaposiform hemangioendothelioma: case report and literature review. Auris Nasus Larynx. 2009;37:258-262.
7. Harper L, Michel JL, Enjolras O, et al. Successful management of a retroperitoneal kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using alpha-interferon. Eur J Pediatr Surg. 2006;16:369-372.
8. Schaffer JV, Fangman W, Bossenbroek NM, et al. Tufted angioma. Dermatol Online J. 2008;14:20.
9. Kamath GH, Bhat RM, Kumar S. Tufted angioma. Int J Dermatol. 2005;44:1045-1047.
10. Debelenko LV, Perez-Atayde AR, Mulliken JB, et al. D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. Mod Pathol. 2005;18:1454-1460.
11. Khoo JJ, Choon SE. Childhood tufted angioma. Pathology. 2006;38:268-270.
12. Chu CY, Hsiao CH, Chiu HC. Transformation between Kaposiform hemangioendothelioma and tufted angioma. Dermatology. 2003;206:334-337.
13. Bienaime A, Rojat-Habib MC, Hesse S, et al. Giant vascular tumour in an adult: tufted angioma or kaposiform heman-gioendothelioma. Ann Dermatol Venereol. 2006;133:553-556.
14. Hu B, Lachman R, Phillips J, et al. Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol. 1998;20:567-569.
15. Vin-Christian K, McCalmont TH, Frieden IJ. Kaposiform hemangioendothelioma. An aggressive, locally invasive vascular tumor that can mimic hemangioma of infancy. Arch Dermatol. 1997;133:1573-1578.
16. Munn SE, Jackson JE, Jones RR. Tufted haemangioma responding to high-dose systemic steroids: a case report and review of the literature. Clin Exp Dermatol. 1994;19:511-514.
17. Deb G. Kaposiform hemangioendothelioma and therapy with interferon-alpha. Med Pediatr Oncol. 2003;41:593.
18. O'Regan GM, Irvine AD, Yao N, et al. Mediastinal and neck kaposiform hemangioendothelioma: report of three cases. Pediatr Dermatol. 2009;26:331-337.
19. Marimsky O, Chaitchik S. Neurotoxicity of interferon alpha. Anticancer Drugs. 1992;3:567-570.
20. Egbert JE, Nelson SC. Neurologic toxicity associated with interferon alfa treatment of capillary hemangioma. J AAPOS. 1997;1:190.
21. Paulino AC, Simon JH, Zhen W, et al. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2000;48: 1489-1495.
22. Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 2002;24:459-462.
23. Thomson K, Pinnock R, Teague L, et al. Vincristine for the treatment of Kasabach-Merritt syndrome: recent New Zealand case experience. NZMedJ. 2007;120:U2418.
24. Drucker AM, Pope E, Mahant S, et al. Vincristine and corticosteroids as first-line treatment of Kasabach-Merritt syndrome in kaposiform hemangioendothelioma. J Cutan Med Surg. 2009;13:155-159.
25. Yesudian PD, Parslew R, Klafowski J, et al. Tufted angioma-associated Kasabach-Merritt syndrome treated with embolization and vincristine. Plast Reconstr Surg. 2008;121:692-693.
26. Hauer J, Graubner U, Konstantopoulos N, et al. Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen. Pediatr Blood Cancer. 2007;49:852-854.
27. Brunton L, Lazo J, Parker K, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11 ed. United States of America: McGraw Hill; 2005.
28. Blei F, Karp N, Rofsky N, et al. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: case report and review of the literature. Pediatr Hematol Oncol. 1998;15: 295-305.
29. Tomiwa K, Mikawa H, Hazama F, et al. Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology. J Neurol. 1983;229:267-272.
30. McCune JS, Lindley C. Appropriateness of maximum-dose guidelines for vincristine. Am J Health Syst Pharm. 1997;54: 1755-1758.